Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

GeoVax Labs, Inc. (GOVX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.2600-0.0500 (-3.82%)
At close: 04:00PM EDT
1.2300 -0.03 (-2.38%)
After hours: 07:59PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.3100
Open1.3400
Bid1.2500 x 900
Ask1.2900 x 1000
Day's Range1.2200 - 1.3400
52 Week Range0.5500 - 7.5000
Volume1,015,123
Avg. Volume9,882,772
Market Cap8.041M
Beta (5Y Monthly)1.89
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • MarketWatch

    Monkeypox cases drove up stock prices for these companies on Monday

    Growing concern about the emergence of monkeypox in Europe and the U.S. has sent shares soaring for several vaccine and drug companies. At least three cases have been confirmed in the U.S. over the past year, including one in an adult male who recently traveled from Canada to Massachusetts. Several companies that developed smallpox vaccines or therapeutics have seen their shares prices jump, and some of those drug makers may be familiar to investors who paid close attention to stocks that got a boost in early 2020 after China first disclosed the outbreak of the new coronavirus that was eventually identified as SARS-CoV-2.

  • Simply Wall St.

    GeoVax Labs (NASDAQ:GOVX) Will Have To Spend Its Cash Wisely

    We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

  • Benzinga

    GeoVax Labs Stock Jumps On US Patent For Malaria Vaccine Candidate

    The U.S. Patent and Trademark Office has issued Patent No. 11,311,612 covering GeoVax Labs Inc's (NASDAQ: GOVX) modified vaccinia Ankara (MVA) vector expressing certain antigens from the malaria parasite. GeoVax's MVA-VLP malaria vaccine candidates incorporate antigens derived from multiple stages of the parasite's life cycle. They are designed to induce an immune response with durable functional antibodies and CD4+ and CD8+ T cell responses. GeoVax's GV-MVA-VLP vaccine platform utilizes modifie

Advertisement
Advertisement